Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) went down by -0.17% from its latest closing price compared to the recent 1-year high of $18.20. The company’s stock price has collected 1.58% of gains in the last five trading sessions. Press Release reported on 05/26/21 that Allscripts Announces New Share Repurchase Program
Is It Worth Investing in Allscripts Healthcare Solutions Inc. (NASDAQ :MDRX) Right Now?
Plus, the 36-month beta value for MDRX is at 1.07. Opinions of the stock are interesting as 5 analysts out of 19 who provided ratings for Allscripts Healthcare Solutions Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 10 rated it as “hold,” and 4 as “sell.”
The average price from analysts is $16.31, which is -$1.76 below the current price. MDRX currently public float of 138.22M and currently shorts hold a 10.12% ratio of that float. Today, the average trading volume of MDRX was 1.66M shares.
MDRX’s Market Performance
MDRX stocks went up by 1.58% for the week, with a monthly jump of 11.63% and a quarterly performance of 15.73%, while its annual performance rate touched 161.28%. The volatility ratio for the week stands at 1.43% while the volatility levels for the past 30 days are set at 2.54% for Allscripts Healthcare Solutions Inc.. The simple moving average for the period of the last 20 days is 4.14% for MDRX stocks with a simple moving average of 29.97% for the last 200 days.
Analysts’ Opinion of MDRX
Many brokerage firms have already submitted their reports for MDRX stocks, with JP Morgan repeating the rating for MDRX by listing it as a “Underweight.” The predicted price for MDRX in the upcoming period, according to JP Morgan is $15 based on the research report published on April 29th of the current year 2021.
Argus gave a rating of “Buy” to MDRX, setting the target price at $14 in the report published on November 11th of the previous year.
MDRX Trading at 10.02% from the 50-Day Moving Average
After a stumble in the market that brought MDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.40% of loss for the given period.
Volatility was left at 2.54%, however, over the last 30 days, the volatility rate increased by 1.43%, as shares surge +10.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.95% upper at present.
During the last 5 trading sessions, MDRX rose by +1.58%, which changed the moving average for the period of 200-days by +95.96% in comparison to the 20-day moving average, which settled at $17.32. In addition, Allscripts Healthcare Solutions Inc. saw 24.31% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at MDRX starting from KLAYKO MICHAEL, who sale 28,000 shares at the price of $18.03 back on Jun 08. After this action, KLAYKO MICHAEL now owns 38,581 shares of Allscripts Healthcare Solutions Inc., valued at $504,952 using the latest closing price.
KLAYKO MICHAEL, the Director of Allscripts Healthcare Solutions Inc., sale 113,000 shares at $18.00 during a trade that took place back on Jun 04, which means that KLAYKO MICHAEL is holding 66,581 shares at $2,034,113 based on the most recent closing price.
Stock Fundamentals for MDRX
Current profitability levels for the company are sitting at:
- -3.84 for the present operating margin
- +34.35 for the gross margin
The net margin for Allscripts Healthcare Solutions Inc. stands at -8.83. The total capital return value is set at -2.70, while invested capital returns managed to touch -6.87. Equity return is now at value 50.40, with 24.10 for asset returns.
Based on Allscripts Healthcare Solutions Inc. (MDRX), the company’s capital structure generated 17.00 points at debt to equity in total, while total debt to capital is 14.53. Total debt to assets is 9.71, with long-term debt to equity ratio resting at 15.67. Finally, the long-term debt to capital ratio is 13.39.
When we switch over and look at the enterprise to sales, we see a ratio of 1.36, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 2.90 and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.23.